NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company • Novartis (ribociclib) Patient/carer groups • Breast Cancer Care • Breast Cancer Now Professional groups • Association of Cancer Physicians • Cancer Research UK • Royal College of Physicians • Royal College of Radiologists Others • Department of Health • NHS England • Welsh Government	General • All Wales Therapeutics and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Welsh Health Specialised Services Committee Possible comparator companies • Accord Healthcare (capecitabine, docetaxel, exemestane, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating) • Amneal Pharma Europe Limited (exemestane) (confidentiality agreement not signed, not participating) • AstraZeneca (fulvestrant) (confidentiality agreement not signed, not participating) • Aurobindo Pharma (tamoxifen) (confidentiality agreement not signed, not participating) • Celgene (paclitaxel) (confidentiality agreement not signed, not participating) • Consilient Health (exemestane) (confidentiality agreement not signed, not participating) • Dr Reddy's Laboratories (capetabine) (confidentiality agreement not signed, not participating)

Consultees	Commentators (no right to submit or appeal)
	• Eli Lilly (gemcitabine) • Hospira (docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating) • Medac UK (capetabine, docetaxel, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating) • Mylan Pharmaceuticals (capecitabine, exemestane, tamoxifen) (confidentiality agreement not signed, not participating) • Novartis (everolimus) • Pfizer (exemestane, palbociclib) • Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating) • Roche (capecitabine) • Sanofi (docetaxel) (confidentiality agreement not signed, not participating) • Seacross Pharmaceuticals (docetaxel) (confidentiality agreement not signed, not participating) • Teva UK (docetaxel, exemestane, gemcitabine, paclitaxel, tamoxifen) (confidentiality agreement not signed, not participating) • Wockhardt UK (tamoxifen) (confidentiality agreement not signed, not participating) • Zentiva (exemestane) (confidentiality agreement not signed, not participating) <u>Relevant research groups</u> • Institute of Cancer Research • National Cancer Research Institute <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.